Equities research analysts expect Spero Therapeutics Inc (NASDAQ:SPRO) to report ($1.04) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have provided estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($1.23) and the highest is ($0.92). Spero Therapeutics reported earnings of ($0.60) per share during the same quarter last year, which would suggest a negative year over year growth rate of 73.3%. The business is expected to report its next earnings results on Thursday, March 12th.
On average, analysts expect that Spero Therapeutics will report full-year earnings of ($3.11) per share for the current financial year, with EPS estimates ranging from ($3.34) to ($2.94). For the next financial year, analysts forecast that the firm will post earnings of ($3.65) per share, with EPS estimates ranging from ($5.27) to ($3.01). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that cover Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.10). The business had revenue of $4.64 million for the quarter, compared to the consensus estimate of $2.03 million. Spero Therapeutics had a negative net margin of 287.11% and a negative return on equity of 43.10%.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Novo Holdings A S bought a new stake in Spero Therapeutics in the second quarter valued at $5,363,000. BlackRock Inc. increased its stake in Spero Therapeutics by 56.0% in the second quarter. BlackRock Inc. now owns 656,778 shares of the company’s stock valued at $7,559,000 after purchasing an additional 235,691 shares in the last quarter. Renaissance Technologies LLC increased its stake in Spero Therapeutics by 89.7% in the second quarter. Renaissance Technologies LLC now owns 214,903 shares of the company’s stock valued at $2,474,000 after purchasing an additional 101,600 shares in the last quarter. AWM Investment Company Inc. increased its stake in Spero Therapeutics by 6.4% in the second quarter. AWM Investment Company Inc. now owns 598,315 shares of the company’s stock valued at $6,887,000 after purchasing an additional 36,019 shares in the last quarter. Finally, State Street Corp increased its stake in Spero Therapeutics by 16.3% in the third quarter. State Street Corp now owns 197,226 shares of the company’s stock valued at $2,091,000 after purchasing an additional 27,695 shares in the last quarter. 48.36% of the stock is owned by institutional investors and hedge funds.
Shares of SPRO stock traded up $0.17 during trading hours on Friday, hitting $11.09. 59,684 shares of the company’s stock traded hands, compared to its average volume of 48,266. The stock’s 50 day simple moving average is $10.99 and its 200 day simple moving average is $10.85. The stock has a market cap of $210.60 million, a PE ratio of -4.27 and a beta of 2.10. Spero Therapeutics has a 12 month low of $5.52 and a 12 month high of $14.48. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.04.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Recommended Story: What is Elliott Wave theory?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.